Quantum Dots in Precision Oncology: Emerging Strategies for Targeted Cancer Therapy

Abstract

Quantum dots (QDs), or nanocrystalline semiconductors, are distinguished by their nanoscale dimensions—generally between 2 and 10 nm—and their exceptional optoelectronic properties derived from the quantum confinement effect. Unlike traditional bulk semiconductors, quantum dots exhibit size-dependent behaviours: altering their size or shape enables tuning of their absorbance and emission spectra, quantum yield, and energy levels. Their discrete electronic states are reminiscent of atomic spectra, earning them the moniker "artificial atoms." These features—such as tenable photoluminescence, robust emission, and pronounced resistance to photobleaching—make QDs highly valuable for biomedical applications, especially in cancer diagnostics, imaging, and theragnostic. Recent advances in QD synthesis have focused on two principal strategies: top-down and bottom-up methodologies. Top-down approaches like electron beam lithography afford precise control over dot placement and dimension, but struggle with scalability. In contrast, bottom-up methods—including microemulsion, sol-gel processing, and colloidal precipitation—provide greater control over particle size, enable uniformity, and are more conducive for biomedical-grade scale production. The introduction of core–shell and multi-shell architectures has markedly advanced QD photostability, diminished non-radiative surface defects, and expanded their application range. These strategies have also facilitated the fabrication of safer, heavy-metal-free quantum dots, such as those based on carbon or silicon, which promise reduced toxicity without sacrificing desirable optical features. To translate QDs into biomedical contexts, surface engineering is pivotal. QDs synthesized by standard methods are generally hydrophobic and prone to aggregation, limiting their aqueous stability and biocompatibility. Functionalization techniques—including ligand exchange, salinization, polymer encapsulation, and PEGylation—render QDs soluble in biological media, extend circulation times, reduce protein adsorption, and minimize acute toxicity. These surface modifications additionally permit the conjugation of drugs, targeting molecules, or responsive linkers, enabling QDs to serve as multiplexed nanoplatforms for drug delivery and biosensing. Within oncology, quantum dots have emerged as next-generation fluorescent biomarkers. Their high quantum yield, broad absorption, and sharp emission, and stability against photobleaching allow for real-time tracking of cancer progression, multiplexed tissue imaging, and sentinel lymph node mapping. Through functionalization with tumour-specific ligands (antibodies, peptides, or aptamers), QDs can selectively accumulate in cancerous tissues, enhancing imaging sensitivity and specificity. Indium phosphide and graphene-based QDs conjugated with targeting moieties, for instance, have demonstrated strong tumour-localized fluorescence in vivo. Carbon, silicon, and black phosphorus-based quantum dots offer alternative solutions with reduced heavy metal risks, adapting QDs for safer clinical translation. Beyond diagnostics, QDs are being integrated as multifunctional therapeutic carriers: they can deliver anticancer agents, nucleic acids, or phototherapeutic substances to tumour sites. Covalent and non-covalent conjugation chemistries—such as EDC-NHS coupling and click-linkage—enable stable drug–QD assemblies with site-specific, stimuli-triggered release profiles (e.g., pH, redox). Nanoconjugates equipped for photodynamic or photothermal therapies uniquely merge imaging and treatment capabilities within a single construct, allowing both real-time process monitoring and targeted therapy delivery. The encapsulation of QDs within polymeric or PEGylated matrices further advances systemic stability and prolongs blood circulation, which is vital for therapeutic efficiency and safety. Despite surging interest, concerns regarding QD toxicity persist, particularly for cadmium-, lead-, and indium-based nanocrystals. Risks include heavy metal ion leakage, chronic bioaccumulation in tissues, and unforeseen effects on organ systems. Several strategies, such as robust core–shell designs, silica or polymer coatings, and development of non-toxic alternatives, seek to mitigate these effects. However, extensive research into pharmacokinetics, biodistribution, long-term toxicity, and clearance mechanisms is imperative before widespread clinical adoption. Looking ahead, quantum dot technology is being geared towards even more sophisticated functionalities: integration with immune-modulatory agents, gene therapies, multimodal imaging techniques, and biosensors for real-time disease monitoring. The convergence of QDs with smart analytics and personalized medicine heralds a future where simultaneous diagnosis, therapy, and monitoring are achieved on a single nanoplatform. Ongoing innovation in material science, clinical safety, and application engineering positions QDs as central players in the evolving field of cancer nanomedicine.